Molecular predictors of response to trastuzumab and lapatinib in breast cancer - PubMed (original) (raw)

Review

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

Francisco J Esteva et al. Nat Rev Clin Oncol. 2010 Feb.

Abstract

Trastuzumab is a monoclonal antibody directed against the human EGFR2 (HER2) protein that has been shown to improve survival in patients with HER2-positive breast cancer. Lapatinib is an oral small-molecule tyrosine kinase inhibitor directed against EGFR and HER2. Lapatinib therapy was shown to prolong the time to progression and increase the rate of response to capecitabine in patients who had received anthracycline-based and taxane-based chemotherapy, and whose tumors had progressed on trastuzumab. HER2 status, either gene copy number or the protein expression level, is the best predictive marker available for assessing response to trastuzumab and lapatinib. Whether the power of this predictive marker is the same in advanced and early-stage cancers is unknown. There is great interest in developing diagnostic tests that predict which patients are more likely to benefit from specific HER2-directed therapies. Novel therapeutics that will overcome resistance to trastuzumab and lapatinib are under intense clinical development. In the future, it will be important to characterize mechanisms of resistance in metastatic tumors to determine which novel targeted therapy will be most appropriate for individual patients.

PubMed Disclaimer

Similar articles

• Lapatinib.
  Voigtlaender M, Schneider-Merck T, Trepel M. Voigtlaender M, et al. Recent Results Cancer Res. 2018;211:19-44. doi: 10.1007/978-3-319-91442-8_2. Recent Results Cancer Res. 2018. PMID: 30069757 Review.
• Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
  Nahta R, Yuan LX, Du Y, Esteva FJ. Nahta R, et al. Mol Cancer Ther. 2007 Feb;6(2):667-74. doi: 10.1158/1535-7163.MCT-06-0423. Mol Cancer Ther. 2007. PMID: 17308062
• A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
  Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. Cameron D, et al. Breast Cancer Res Treat. 2008 Dec;112(3):533-43. doi: 10.1007/s10549-007-9885-0. Epub 2008 Jan 11. Breast Cancer Res Treat. 2008. PMID: 18188694 Clinical Trial.
• Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
  Medina PJ, Goodin S. Medina PJ, et al. Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008. Clin Ther. 2008. PMID: 18803986 Review.
• Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
  Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Diéras V, et al. Lancet Oncol. 2017 Jun;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1. Epub 2017 May 16. Lancet Oncol. 2017. PMID: 28526536 Free PMC article. Clinical Trial.

Cited by

• Inhibition of mutationally activated HER2.
  Collins SJ, Guo J, Rizzo RC, Miller WT. Collins SJ, et al. Chem Biol Drug Des. 2023 Jan;101(1):87-102. doi: 10.1111/cbdd.14125. Epub 2022 Aug 27. Chem Biol Drug Des. 2023. PMID: 36029027 Free PMC article.
• A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
  Puig T, Aguilar H, Cufí S, Oliveras G, Turrado C, Ortega-Gutiérrez S, Benhamú B, López-Rodríguez ML, Urruticoechea A, Colomer R. Puig T, et al. Breast Cancer Res. 2011;13(6):R131. doi: 10.1186/bcr3077. Epub 2011 Dec 16. Breast Cancer Res. 2011. PMID: 22177475 Free PMC article.
• The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma.
  Samuel N, Hudson TJ. Samuel N, et al. Nat Rev Gastroenterol Hepatol. 2011 Dec 20;9(2):77-87. doi: 10.1038/nrgastro.2011.215. Nat Rev Gastroenterol Hepatol. 2011. PMID: 22183185 Review.
• HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.
  Boulbes DR, Arold ST, Chauhan GB, Blachno KV, Deng N, Chang WC, Jin Q, Huang TH, Hsu JM, Brady SW, Bartholomeusz C, Ladbury JE, Stone S, Yu D, Hung MC, Esteva FJ. Boulbes DR, et al. Mol Oncol. 2015 Mar;9(3):586-600. doi: 10.1016/j.molonc.2014.10.011. Epub 2014 Nov 11. Mol Oncol. 2015. PMID: 25435280 Free PMC article.
• Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
  Teplinsky E, Esteva FJ. Teplinsky E, et al. Curr Oncol Rep. 2015 Oct;17(10):46. doi: 10.1007/s11912-015-0471-z. Curr Oncol Rep. 2015. PMID: 26314739 Review.

References

1. 1. J Natl Cancer Inst. 2007 Apr 18;99(8):628-38 - PubMed
2. 1. Mol Cancer Ther. 2007 Feb;6(2):667-74 - PubMed
3. 1. N Engl J Med. 2008 Mar 27;358(13):1409-11 - PubMed
4. 1. Ann Oncol. 2008 Jun;19(6):1068-74 - PubMed
5. 1. J Clin Oncol. 1996 Mar;14(3):737-44 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal